Abstract
The repertoire of small-molecular-weight substances present in cells, tissue and body fluids are known as the metabolites. The global analysis of metabolites, such as by high-resolution 1H nuclear magnetic resonance spectroscopy and mass spectrometry, is integral to the rapidly expanding field of metabolomics, which is making progress in various diseases. In the area of cancer and metabolic phenotype, the integrated analysis of metabolites may provide a powerful platform for detecting changes related to cancer diagnosis and discovering novel biomarkers. In this review, metabolomics including the technologies in metabolomics research and extracting information from metabolomics datasets are described. Then we discuss the challenges and opportunities in metabolomics for finding metabolic processes in cancer and discovering novel cancer biomarkers. Finally, we assess the clinical applicability of metabolomics.
Keywords: Biomarker identification, cancer, metabolomics, body fluids, high-resolution, mass spectrometry, biomarkers, biochemical processes, DNA, RNA, protein, concentrations, interactions, gene expression, endogenous, metabolities, NMR spectroscopy, biofluids, pattern recognition (PR)
Combinatorial Chemistry & High Throughput Screening
Title: Metabolomics: A Revolution for Novel Cancer Marker Identification
Volume: 15 Issue: 3
Author(s): Qian Bu, Yina Huang, Guangyan Yan, Xiaobo Cen and Ying-Lan Zhao
Affiliation:
Keywords: Biomarker identification, cancer, metabolomics, body fluids, high-resolution, mass spectrometry, biomarkers, biochemical processes, DNA, RNA, protein, concentrations, interactions, gene expression, endogenous, metabolities, NMR spectroscopy, biofluids, pattern recognition (PR)
Abstract: The repertoire of small-molecular-weight substances present in cells, tissue and body fluids are known as the metabolites. The global analysis of metabolites, such as by high-resolution 1H nuclear magnetic resonance spectroscopy and mass spectrometry, is integral to the rapidly expanding field of metabolomics, which is making progress in various diseases. In the area of cancer and metabolic phenotype, the integrated analysis of metabolites may provide a powerful platform for detecting changes related to cancer diagnosis and discovering novel biomarkers. In this review, metabolomics including the technologies in metabolomics research and extracting information from metabolomics datasets are described. Then we discuss the challenges and opportunities in metabolomics for finding metabolic processes in cancer and discovering novel cancer biomarkers. Finally, we assess the clinical applicability of metabolomics.
Export Options
About this article
Cite this article as:
Bu Qian, Huang Yina, Yan Guangyan, Cen Xiaobo and Zhao Ying-Lan, Metabolomics: A Revolution for Novel Cancer Marker Identification, Combinatorial Chemistry & High Throughput Screening 2012; 15 (3) . https://dx.doi.org/10.2174/138620712799218563
DOI https://dx.doi.org/10.2174/138620712799218563 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Thyroid Hormones and Cardiovascular System: From Bench to Bedside
Current Drug Therapy Atypical Neurotransmitters and the Neurobiology of Depression
CNS & Neurological Disorders - Drug Targets Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants
Current Pharmaceutical Design Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets Mechanisms of Beta-Blockers Action in Patients with Heart Failure
Reviews on Recent Clinical Trials A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence
Current Drug Targets - Cardiovascular & Hematological Disorders Puerarin Stimulates Osteogenic Differentiation and Bone Formation Through the ERK1/2 and p38-MAPK Signaling Pathways
Current Molecular Medicine Beta-Blockers are Associated with Decreased In-Hospital Mortality and Stroke in Acute Decompensated Heart Failure: Findings from a Retrospective Analysis of a 22-Year Registry in the Middle East (1991-2013)
Current Vascular Pharmacology Metabolic Therapy of Heart Failure
Current Pharmaceutical Design Drug Eluting Coronary Artery Stents
Current Drug Delivery Role of Adiponectin in Obesity, Hypertension, and Metabolic Syndrome
Current Hypertension Reviews Pharmacogenomics of Oral Antithrombotic Drugs
Current Pharmaceutical Design Update on the Evaluation and Management of Brief Resolved Unexplained Events (Previously Apparent Life-Threatening Events)
Reviews on Recent Clinical Trials Have We New Therapeutic Strategies in the Treatment of Renovascular Nephropathy?
Current Vascular Pharmacology Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs as Cyclooxygenase Inhibitors: State of the Art, Barriers and Perspectives
Current Computer-Aided Drug Design Postmenopausal Hormone Therapy
Current Women`s Health Reviews Rational Discovery of Novel Squalene Synthase Inhibitors through Pharmacophore Modelling
Current Computer-Aided Drug Design Can Statin be a Novel Pharmacophore for Antidiabetic Activity?
Mini-Reviews in Medicinal Chemistry Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Radial Distribution of Elasticity in Porcine Thoracic Aorta
Vascular Disease Prevention (Discontinued)